Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course
Since its licensing in 1971, the synthetic compound inosine pranobex has been effectively combating viral infections, including herpes zoster, varicella, measles, and infections caused by the herpes simplex virus, human papillomavirus, Epstein–Barr virus, cytomegalovirus, and respiratory viruses. Wi...
Main Authors: | Jiří Beran, Marián Špajdel, Jiří Slíva |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-11-01
|
Series: | Viruses |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4915/13/11/2246 |
Similar Items
-
Inosine Pranobex Significantly Decreased the Case-Fatality Rate among PCR Positive Elderly with SARS-CoV-2 at Three Nursing Homes in the Czech Republic
by: Jiří Beran, et al.
Published: (2020-12-01) -
ROLE OF INOSINE PRANOBEX IN MANAGEMENT OF HPV-ASSOCIATED DISEASES: PROBLEMS AND PROSPECTIVE
by: V. O. Bitsadze, et al.
Published: (2016-10-01) -
Use of inosine pranobex in frequently ill children
by: V. N. Drozdov, et al.
Published: (2019-11-01) -
Evaluation of the influence of Inosine pranobex on the matrix protein system in patients with chronic viral cervicitis
by: T. A. Nevezhkina, et al.
Published: (2023-06-01) -
ACUTE RESPIRATORY INFECTIONS IN CHILDREN: PROBLEM OF POLYPHARMACY
by: Y. L. Mizernitsky, et al.
Published: (2016-12-01)